Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial

Conventional nonsteroidal anti-inflammatory drugs (NSAIDs) nonspecifically inhibit cyclooxygenase-1 (COX-1), an enzyme critical to normal platelet function, and COX-2, which mediates inflammatory response mechanisms. Celecoxib, an antiarthritic agent that inhibits COX-2 but spares COX-1 at therapeutic doses, is expected to have minimal effects on platelet function. A double-blind, randomized, placebo-controlled study of 10 days' duration was conducted in 24 healthy adults to compare the effects on platelet function of a supratherapeutic dose of celecoxib (600 mg bid) with a standard dose of naproxen (500 mg bid), a conventional NSAID. Ex vivo platelet aggregation in response to standard agonists (collagen, arachidonate, or U46619 [a thromboxane A2 receptor agonist]), bleeding time, and serum thromboxane B2 (TxB2) level were measured. Unlike celecoxib or placebo, naproxen produced statistically significant reductions in platelet aggregation and serum TxB2 levels and increased bleeding time. The results indicate that even at supratherapeutic doses, celecoxib will not interfere with normal mechanisms of platelet aggregation and hemostasis, supporting the premise that celecoxib is COX-1 sparing relative to conventional NSAIDs.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T C. Cheetham, G. Levy, F. Niu, and F. Bixler Gastrointestinal Safety of Nonsteroidal Antiinflammatory Drugs and Selective Cyclooxygenase-2 Inhibitors in Patients on Warfarin Ann. Pharmacother., November 1, 2009; 43(11): 1765 - 1773. [Abstract] [Full Text] [PDF]

				S. S. Reuben, E. F. Ekman, and D. Charron Evaluating the Analgesic Efficacy of Administering Celecoxib as a Component of Multimodal Analgesia for Outpatient Anterior Cruciate Ligament Reconstruction Surgery Anesth. Analg., July 1, 2007; 105(1): 222 - 227. [Abstract] [Full Text] [PDF]

				E. F. Ekman, G. Ruoff, K. Kuehl, L. Ralph, P. Hormbrey, J. Fiechtner, and M. F. Berger The COX-2 Specific Inhibitor Valdecoxib Versus Tramadol in Acute Ankle Sprain: A Multicenter Randomized, Controlled Trial Am. J. Sports Med., June 1, 2006; 34(6): 945 - 955. [Abstract] [Full Text] [PDF]

				D. Pratico and J.-M. Dogne Selective Cyclooxygenase-2 Inhibitors Development in Cardiovascular Medicine Circulation, August 16, 2005; 112(7): 1073 - 1079. [Full Text] [PDF]

				S C. Jones Relative Thromboembolic Risks Associated with COX-2 Inhibitors Ann. Pharmacother., July 1, 2005; 39(7): 1249 - 1259. [Abstract] [Full Text] [PDF]

				N. A. Goldenberg, L. Jacobson, and M. J. Manco-Johnson Brief Communication: Duration of Platelet Dysfunction after a 7-Day Course of Ibuprofen Ann Intern Med, April 5, 2005; 142(7): 506 - 509. [Abstract] [Full Text] [PDF]

				S. S. Reuben and E. F. Ekman The Effect of Cyclooxygenase-2 Inhibition on Analgesia and Spinal Fusion J. Bone Joint Surg. Am., March 1, 2005; 87(3): 536 - 542. [Abstract] [Full Text] [PDF]

				F. T. Shaya, S. W. Blume, C. M. Blanchette, M. R. Weir, and C. D. Mullins Selective Cyclooxygenase-2 Inhibition and Cardiovascular Effects: An Observational Study of a Medicaid Population Arch Intern Med, January 24, 2005; 165(2): 181 - 186. [Abstract] [Full Text] [PDF]

				A. J. Dannenberg, S. M. Lippman, J. R. Mann, K. Subbaramaiah, and R. N. DuBois Cyclooxygenase-2 and Epidermal Growth Factor Receptor: Pharmacologic Targets for Chemoprevention J. Clin. Oncol., January 10, 2005; 23(2): 254 - 266. [Abstract] [Full Text] [PDF]

				R. M. Pertusi Selective Cyclooxygenase Inhibition in Pain Management J Am Osteopath Assoc, November 1, 2004; 104(11_suppl): 19S - 24S. [Abstract] [Full Text] [PDF]

				M. A. Buerkle, S. Lehrer, H.-Y. Sohn, P. Conzen, U. Pohl, and F. Krotz Selective Inhibition of Cyclooxygenase-2 Enhances Platelet Adhesion in Hamster Arterioles In Vivo Circulation, October 5, 2004; 110(14): 2053 - 2059. [Abstract] [Full Text] [PDF]

				D. L. Simmons, R. M. Botting, and T. Hla Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition Pharmacol. Rev., September 1, 2004; 56(3): 387 - 437. [Abstract] [Full Text] [PDF]

				E. F. Ekman and L. A. Koman Acute Pain Following Musculoskeletal Injuries and Orthopaedic Surgery. Mechanisms and Management J. Bone Joint Surg. Am., June 1, 2004; 86(6): 1316 - 1327. [Full Text] [PDF]

				T. D. WARNER and J. A. MITCHELL Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic FASEB J, May 1, 2004; 18(7): 790 - 804. [Abstract] [Full Text] [PDF]

				K. Stengaard-Pedersen, R. Ekesbo, A.-L. Karvonen, and M. Lyster Celecoxib 200 mg q.d. is efficacious in the management of osteoarthritis of the knee or hip regardless of the time of dosing Rheumatology, May 1, 2004; 43(5): 592 - 595. [Abstract] [Full Text] [PDF]

				T. R. Hegi, T. Bombeli, B. Seifert, P. C. Baumann, U. Haller, M. P. Zalunardo, T. Pasch, and D. R. Spahn Effect of rofecoxib on platelet aggregation and blood loss in gynaecological and breast surgery compared with diclofenac Br. J. Anaesth., April 1, 2004; 92(4): 523 - 531. [Abstract] [Full Text] [PDF]

				E J Hall and N P Sykes Analgesia for patients with advanced disease: 2 Postgrad. Med. J., April 1, 2004; 80(942): 190 - 195. [Abstract] [Full Text] [PDF]

				W. Dai and R. A. Kloner Relationship Between Cyclooxygenase-2 Inhibition and Thrombogenesis Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1): 51 - 59. [Abstract] [PDF]

				D. Layton, K. Hughes, S. Harris, and S. A.W. Shakir Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data Rheumatology, November 1, 2003; 42(11): 1354 - 1364. [Abstract] [Full Text] [PDF]

				J. Burke, W. K. Kraft, H. E. Greenberg, M. Gleave, G. M. Pitari, S. VanBuren, J. A. Wagner, and S. A. Waldman Relationship of Arachidonic Acid Concentration to Cyclooxygenase-Dependent Human Platelet Aggregation J. Clin. Pharmacol., September 1, 2003; 43(9): 983 - 989. [Abstract] [Full Text] [PDF]

				P. J. S. Koo Acute Pain Management Journal of Pharmacy Practice, August 1, 2003; 16(4): 231 - 248. [Abstract] [PDF]

				E.A.J. Knijff-Dutmer, J. Van der Palen, G. Schut, and M.A.F.J. Van de Laar The influence of cyclo-oxygenase specificity of non-steroidal anti-inflammatory drugs on bleeding complications in concomitant coumarine users QJM, July 1, 2003; 96(7): 513 - 520. [Abstract] [Full Text] [PDF]

				N. M. Gajraj Cyclooxygenase-2 Inhibitors Anesth. Analg., June 1, 2003; 96(6): 1720 - 1738. [Full Text] [PDF]

				P. T. Leese, D. P. Recker, and J. D. Kent The COX-2 Selective Inhibitor, Valdecoxib, Does Not Impair Platelet Function in the Elderly: Results of a Randomized Controlled Trial J. Clin. Pharmacol., May 1, 2003; 43(5): 504 - 513. [Abstract] [Full Text] [PDF]

				J. J. Yuan, D.-c. Yang, J. Y. Zhang, R. Bible Jr., A. Karim, and J. W. A. Findlay Disposition of a Specific Cyclooxygenase-2 Inhibitor, Valdecoxib, in Human Drug Metab. Dispos., September 1, 2002; 30(9): 1013 - 1021. [Abstract] [Full Text] [PDF]

				D. J. Watson, T. Rhodes, B. Cai, and H. A. Guess Lower Risk of Thromboembolic Cardiovascular Events With Naproxen Among Patients With Rheumatoid Arthritis Arch Intern Med, May 27, 2002; 162(10): 1105 - 1110. [Abstract] [Full Text] [PDF]

				E. A. J. Knijff-Dutmer, E. M. Kalsbeek-Batenburg, J. Koerts, and M. A. F. J. van de Laar Platelet function is inhibited by non-selective non-steroidal anti-inflammatory drugs but not by cyclo-oxygenase-2-selective inhibitors in patients with rheumatoid arthritis Rheumatology, April 1, 2002; 41(4): 458 - 461. [Abstract] [Full Text] [PDF]

				B. Hinz and K. Brune Cyclooxygenase-2---10 Years Later J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 367 - 375. [Abstract] [Full Text] [PDF]

				D. Riendeau, M. D. Percival, C. Brideau, S. Charleson, D. Dubé, D. Ethier, J.-P. Falgueyret, R. W. Friesen, R. Gordon, G. Greig, et al. Etoricoxib (MK-0663): Preclinical Profile and Comparison with Other Agents That Selectively Inhibit Cyclooxygenase-2 J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 558 - 566. [Abstract] [Full Text]

				P. A. MOORE and E. V. HERSH Celecoxib and rofecoxib: The role of COX-2 inhibitors in dental practice J Am Dent Assoc, April 1, 2001; 132(4): 451 - 456. [Abstract] [Full Text] [PDF]

				Are {blacktriangledown}rofecoxib and {blacktriangledown}celecoxib safer NSAIDS? DTB, November 1, 2000; 38(11): 81 - 86. [Abstract] [Full Text] [PDF]

				M. Ouellet, D. Riendeau, and M. D. Percival A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin PNAS, December 4, 2001; 98(25): 14583 - 14588. [Abstract] [Full Text] [PDF]